AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report

GlaxoSmithKline’s $5.1 billion acquisition of Tesaro marked the company’s great pivot to oncology as championed by CEO Emma Walmsley. But just as the British pharma works hard to reap the deal’s financial benefits, its rival is taking a stab at its gains in court.